Home › Hereditary Sensory and Autonomic Neuropathies › Tennessee
Pag-aaral pangklinika para sa Hereditary Sensory and Autonomic Neuropathies sa Tennessee
6 pag-aaral para sa Hereditary Sensory and Autonomic Neuropathies ang naghahanap ng mga kalahok sa mga site sa Tennessee.
Mga Lungsod sa Tennessee
Opisyal na teksto ng pag-aaral (English)
Study of ACR-2316 in Specific Advanced Solid Tumors
- Tennessee Oncology, Franklin
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06667141A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Tennessee Oncology, PLLC, Chattanooga
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- SCRI Oncology Partners, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT07558733A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Sarah Cannon Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Kababaihan · Na-update Abr 22, 2026 · NCT05683418Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
Nagre-recruitObservasyonal na pag-aaral
Edad 1 hanggang 100 · Lahat ng kasarian · Na-update Abr 1, 2026 · NCT05868629Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.